Gene Testing to Help in the Diagnosis & Treatment of Childhood Brain

Status Completed

Clinical Trial Summary

RATIONALE: Analyzing the number and structure of genes found in a child's cancer cells may help doctors improve methods of diagnosing and treating children with brain tumors.

PURPOSE: This clinical trial is studying the number and structure of genes in cancer cells of children with brain tumors.

Clinical Trial Description

OBJECTIVES:

- Determine the chromosomal gains and losses by DNA ploidy analysis and comparative genomic hybridization in patients with primitive neuroectodermal tumors or medulloblastomas.

- Determine the frequency of specific chromosomal abnormalities, including deletions of chromosomal regions 6, 17, and 22, in these patients.

- Perform a statistical analysis to determine possible associations of chromosomal abnormalities and DNA ploidy with patient age, tumor histology, tumor location, extent of disease, and event-free survival.

OUTLINE: DNA ploidy analysis will be performed to determine the overall level of aneuploidy. The results are compared to the comparative genomic hybridization (CGH) analysis, which is used to demonstrate tumor-specific losses or gains, including amplification, of specific chromosomal regions. Tumors are also screened for specific abnormalities by fluorescent in situ hybridization (FISH), which detects chromosomal rearrangements, including balanced translocations, deletions, amplifications, etc. PCR-based microsatellite polymorphism analysis may also be performed.

Primitive neuroectodermal tumors (PNETs) are screened by FISH with a distal 17p13.3 cosmid and a 17q25 cosmid to identify tumors with a 17p deletion. Atypical teratoid/rhabdoid tumors and PNETs without a 17p deletion are screened by FISH with a series of cosmids from 22q11.2. PNETs are also screened by interphase FISH with cosmids from chromosome 6 to identify tumors with deletions.

Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.

PROJECTED ACCRUAL: This study will accrue 360 specimens. ;

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00003096
Study type	Observational
Source	Children's Oncology Group
Contact
Status	Completed
Phase	N/A
Start date	December 1996
Completion date	March 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02846038` - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Completed	`NCT02537106` - A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation	N/A
Completed	`NCT01951950` - Nicardipine vs Esmolol Craniotomy Emergence	Phase 1
Completed	`NCT01222780` - To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer	Phase 1
Completed	`NCT00873184` - Study of Massage Therapy Within a Brain Tumor Setting	N/A
Active, not recruiting	`NCT01115777` - Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
Completed	`NCT00724191` - Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
Completed	`NCT00003935` - Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma	Phase 1
Recruiting	`NCT04128306` - Brain Areas of Time-To-Contact Perception: an Awake Surgery Study	N/A
Recruiting	`NCT05202899` - Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy	Phase 4
Completed	`NCT00707343` - [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors	Phase 1
Completed	`NCT00850278` - Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors	N/A
Completed	`NCT00528437` - Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors	Phase 2
Terminated	`NCT00107471` - Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma	Phase 1/Phase 2
Completed	`NCT00187174` - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors	Phase 1
Completed	`NCT00135876` - Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients	Phase 3
Completed	`NCT00062478` - Study of Karenitecin (BNP1350) in Patients With Brain Tumors	Phase 2
Completed	`NCT00241670` - Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid	Phase 3
Not yet recruiting	`NCT01445691` - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery	Phase 2
Terminated	`NCT01018290` - Navigated Transcranial Magnetic Stimulation in Tumor Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms